Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

被引：8
|
作者：
Slade, Michael [1 ]
Martin, Thomas G. [2 ]
Nathwani, Nitya [3 ]
Fiala, Mark A. [1 ]
Rettig, Michael P. [1 ]
Gao, Feng [1 ]
Deol, Abhinav [4 ]
Buadi, Francis K. [5 ]
Kaufman, Jonathan L. [6 ]
Hofmeister, Craig C. [6 ]
Gregory, Tara K. [7 ]
Berdeja, Jesus [8 ]
Chari, Ajai [9 ]
Rosko, Ashley [10 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63130 USA
[2] Univ Calif San Francisco, San Francisco, CA USA
[3] City Hope Comprehens Canc Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Mayo Clin, Rochester, MN USA
[6] Emory Univ, Atlanta, GA USA
[7] Sarah Cannon Res Inst, Denver, CO USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Icahn Sch Med Mt Sinai, New York, NY USA
[10] Ohio State Univ, Columbus, OH 43210 USA
来源：
LEUKEMIA | 2022年 / 36卷 / 12期
基金：
美国国家卫生研究院;
关键词：
STEM-CELL TRANSPLANTATION; ORAL IXAZOMIB; BORTEZOMIB;
D O I：
10.1038/s41375-022-01691-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2917 / 2921
页数：5
相关论文
共 50 条
  • [31] Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
    Sborov, Douglas W.
    Benson, Don M.
    Williams, Nita
    Huang, Ying
    Bowers, Mindy A.
    Humphries, Kristina
    Efebera, Yvonne
    Devine, Steven
    Hofmeister, Craig C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 74 - 83
  • [32] Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial
    Vij, Ravi
    Nathwani, Nitya
    Martin, Thomas G., III
    Fiala, Mark A.
    Deol, Abhinav
    Buadi, Francis K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Gregory, Tara
    Berdeja, Jesus G.
    Chari, Ajai
    Rosko, Ashley E.
    [J]. BLOOD, 2018, 132
  • [33] Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Patel, Krina K.
    Shah, Jatin J.
    Feng, Lei
    Lee, Hans C.
    Manasanch, Elisabet E.
    Thomas, Sheeba K.
    Weber, Donna M.
    Munoz, Silvia C.
    Morphey, Ashley
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Orlowski, Robert Z.
    [J]. BLOOD, 2017, 130
  • [34] Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Weber, Donna
    Thomas, Sheeba K.
    Wang, Michael
    Turturro, Francesco
    Qazilbash, Muzaffar H.
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday R.
    Manasanch, Elisabet E.
    Munoz, Silvia C.
    Landry, Ashley
    Mendoza, Kathleen
    Nieto, Yago
    Champlin, Richard E.
    Orlowski, Robert Z.
    [J]. BLOOD, 2015, 126 (23)
  • [35] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
    Zhuang, Zhe
    Tian, Ying
    Yu, Hong
    Shi, Lei
    Tian, Wei-wei
    Liu, Qinhua
    Zou, Dongmei
    Dong, Fei
    Ma, Yanping
    Feng, Ru
    Liu, Shuangjiao
    Liu, Hui
    Jing, Hongmei
    Sun, Wanling
    Ma, Liang-Ming
    Bao, Li
    Wu, Yin
    Chen, Wenming
    Zhuang, Junling
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S54 - S55
  • [36] BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL
    Sakagute, M.
    Tanaka, P. Y.
    Duva, A.
    Rigolon, J.
    [J]. VALUE IN HEALTH, 2019, 22 : S459 - S459
  • [37] BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA
    Pyadushkina, E.
    Derkach, E., V
    Boyarskaya, T.
    [J]. VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [38] Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
    Zhuang, Zhe
    Yu, Hong
    Liu, Qinhua
    Zou, Dongmei
    Shi, Lei
    Tian, Ying
    Dong, Fei
    Ma, Yanping
    Tian, Wei-wei
    Feng, Ru
    Liu, Shuangjiao
    Liu, Hui
    Ma, Liang-Ming
    Jing, Hongmei
    Chen, Wenming
    Wu, Yin
    Bao, Li
    Sun, Wanling
    Fu, Rong
    Zhuang, Junling
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S113 - S113
  • [39] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
    Moreau, Philippe
    Hulin, Cyrille
    Caillot, Denis
    Marit, Gerald
    Perrot, Aurore
    Garderet, Laurent
    Facon, Thierry
    Benboubker, Lotfi
    Karlin, Lionel
    Tiab, Mourad
    Arnulf, Bertrand
    Fermand, Jean-Paul
    Leleu, Xavier
    Touzeau, Cyrille
    Roussel, Murielle
    Planche, Lucie
    Minvielle, Stephane
    Bene, Marie-Christine
    Avet-Loiseau, Herve
    Dejoie, Thomas
    Attal, Michel
    [J]. BLOOD, 2016, 128 (22)
  • [40] Ixazomib, lenalidomide and dexamethasone: a winning first all-oral triplet for multiple myeloma
    Paillassa, Jerome
    [J]. HEMATOLOGIE, 2016, 22 (03): : 181 - +
12345